ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "arthritis and treatment"

  • Abstract Number: 1437 • 2016 ACR/ARHP Annual Meeting

    Netrin-1 and Its Receptor Unc5b Are Novel Targets for the Treatment of Inflammatory Arthritis

    Aranzazu Mediero1, Tuere Wilder2, Bhama Ramkhelawon3, Kathryn Moore3 and Bruce Cronstein4, 1Medicine, Divison of Translational Medicine, NYU School of Medicine, New York City, NY, 2Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, 3Leon H. Charney Division of Cardiology, Department of Medicine,, NYU School of Medicine, New York, NY, 4Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY

    Background/Purpose:  Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation and destruction of joints. Netrin-1, a laminin-like matrix protein that acts as a…
  • Abstract Number: 2559 • 2015 ACR/ARHP Annual Meeting

    PRO-Resolving Mediators Issued from Apoptotic CELL Efferocytosis (SUPERMAPO) Modulate Antigen Presenting CELL Properties Toward a Tolerogenic Profile: Efficacy in the Treatment of Collagen- Induced Arthritis

    Francis Bonnefoy1, Romain Vallion2, Mélanie Couturier3, Anna Daoui3, Eric Toussirot4 and Sylvain Perruche1, 1UMR1098 INSERM, EFS Bourgogne Franche Comté, Besançon, France, 2INSERM UMR 1098, EFS Bourgogne Franche Comté, Besançon, France, 3INSERM UMR1098, EFS Bourgogne Franche Comté, Besançon, France, 4Service de Rhumatologie, CHU J Minjoz, Besancon, France

    Background/Purpose: Pro-resolving mediators produced by macrophages eliminating apoptotic effector cells during the resolution of inflammation have been shown to stop inflammation, favor tissue repair and…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology